Free Trial

This company has been marked as potentially delisted and may not be actively trading.

TenX Keane Acquisition (TENK) Competitors

TENK vs. ATOS, HURA, PROC, TNYA, HLVX, CTNM, MCRB, ANIX, SAVA, and COYA

Should you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include Atossa Genetics (ATOS), TuHURA Biosciences (HURA), Procaps Group (PROC), Tenaya Therapeutics (TNYA), HilleVax (HLVX), Contineum Therapeutics (CTNM), Seres Therapeutics (MCRB), Anixa Biosciences (ANIX), Cassava Sciences (SAVA), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical products" industry.

TenX Keane Acquisition vs. Its Competitors

TenX Keane Acquisition (NASDAQ:TENK) and Atossa Genetics (NASDAQ:ATOS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, Atossa Genetics had 1 more articles in the media than TenX Keane Acquisition. MarketBeat recorded 1 mentions for Atossa Genetics and 0 mentions for TenX Keane Acquisition. Atossa Genetics' average media sentiment score of 1.89 beat TenX Keane Acquisition's score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company Overall Sentiment
TenX Keane Acquisition Neutral
Atossa Genetics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TenX Keane AcquisitionN/AN/AN/AN/AN/A
Atossa GeneticsN/AN/A-$25.50M-$0.21-4.21

70.5% of TenX Keane Acquisition shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 22.9% of TenX Keane Acquisition shares are held by company insiders. Comparatively, 7.6% of Atossa Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Atossa Genetics has a consensus price target of $6.17, suggesting a potential upside of 597.59%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than TenX Keane Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TenX Keane Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Atossa Genetics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

TenX Keane Acquisition's return on equity of 0.00% beat Atossa Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
TenX Keane AcquisitionN/A N/A N/A
Atossa Genetics N/A -33.90%-31.53%

Summary

Atossa Genetics beats TenX Keane Acquisition on 6 of the 10 factors compared between the two stocks.

Get TenX Keane Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TENK vs. The Competition

MetricTenX Keane AcquisitionHolding Offices Industry SectorNASDAQ Exchange
Market Cap$10.45M$208.01M$2.03B$9.40B
Dividend YieldN/A3.15%13.72%4.09%
P/E RatioN/A1.8812.3319.86
Price / SalesN/A547.872,533,931.5198.68
Price / CashN/A109.2857.5157.53
Price / BookN/A8.783.215.71
Net IncomeN/A-$10.64M-$461.08M$257.80M

TenX Keane Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TENK
TenX Keane Acquisition
N/A$1.57
+1.9%
N/A-86.5%$10.45MN/A0.00N/AGap Down
High Trading Volume
ATOS
Atossa Genetics
3.1569 of 5 stars
$0.90
+6.2%
$6.17
+585.2%
-36.3%$109.43MN/A-4.298Positive News
HURA
TuHURA Biosciences
1.5172 of 5 stars
$2.49
+0.4%
$12.67
+408.7%
N/A$108.33MN/A0.00N/A
PROC
Procaps Group
N/A$0.95
-40.3%
N/A-62.2%$107.18M$409.92M0.004,900Gap Down
High Trading Volume
TNYA
Tenaya Therapeutics
3.4988 of 5 stars
$0.67
+6.1%
$6.25
+831.3%
-81.0%$102.94MN/A-0.58110
HLVX
HilleVax
2.0832 of 5 stars
$2.12
+3.4%
$2.00
-5.7%
+15.8%$102.79MN/A-0.9920Positive News
CTNM
Contineum Therapeutics
3.6817 of 5 stars
$4.01
+2.3%
$22.50
+461.1%
-82.4%$101.42M$50M-2.0431High Trading Volume
MCRB
Seres Therapeutics
3.4616 of 5 stars
$12.38
+6.7%
$73.67
+495.0%
-45.0%$101.30M$126.32M-2.69330Positive News
ANIX
Anixa Biosciences
2.9644 of 5 stars
$3.15
+0.3%
$9.00
+185.7%
+4.3%$101.14M$210K-8.295
SAVA
Cassava Sciences
4.1614 of 5 stars
$2.19
+5.3%
$54.50
+2,388.6%
-84.7%$100.48MN/A-1.4630Positive News
COYA
Coya Therapeutics
1.7854 of 5 stars
$6.22
+3.7%
$16.50
+165.3%
-24.5%$100.35M$3.55M-5.816Gap Up

Related Companies and Tools


This page (NASDAQ:TENK) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners